Business Context and Reporting Period
This Form 8-K Current Report from Assembly Biosciences, Inc. covers events occurring on May 28, 2015, specifically the Company's 2015 Annual Meeting of Stockholders. The filing details the departure of a director, the election of new directors, and the results of an advisory vote on executive compensation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Director Departure and Transition
Russell H. Ellison, MD, concluded his term as a director and did not stand for re-election. The departure was not due to any disagreement with the Company. Dr. Ellison will continue to serve as a Senior Advisor and head of the microbiome development program.
Election of Directors
Stockholders elected six directors to one-year terms expiring in 2016. Voting statistics for the 12,265,273 shares present or represented by proxy were as follows:
| Nominee | Votes For | Votes Withheld |
|---|---|---|
| Anthony Altig | 12,263,237 | 2,036 |
| Mark Auerbach | 11,407,696 | 857,577 |
| Richard DiMarchi | 12,263,238 | 2,035 |
| Myron Z. Holubiak | 11,559,375 | 705,898 |
| William Ringo | 11,995,341 | 269,932 |
| Derek Small | 12,263,038 | 2,235 |
There were 4,818,874 broker non-votes regarding the election of directors.
Advisory Vote on Executive Compensation
Stockholders approved the compensation of named executive officers on an advisory basis. The results were:
- For: 10,479,228
- Against: 908,364
- Abstained: 877,681
- Broker Non-Votes: 4,818,874
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or specific risk factors. Management commentary is limited to the confirmation that Dr. Ellison's departure involved no disagreement and his continued role in the microbiome development program as the Company approaches key milestones.
Key Facts for Investor Verification
- Verify the continued involvement of Russell H. Ellison, MD, as Senior Advisor and head of the microbiome development program.
- Confirm the composition of the Board of Directors following the election of the six new directors.
- Note the significant number of broker non-votes (4,818,874) relative to the total shares entitled to vote (17,084,147).
- Review the Company's proxy statements filed on April 13, 2015, and May 14, 2015, for detailed compensation disclosures referenced in the advisory vote.